Proxima Capital Management’s Trinity Biotech TRIB Stock Holding History

Proxima Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-196	Closed	-$165K	–	39
2017 Q3	$165K	Hold	196	–	–	0.09%	36
2017 Q2	$176K	Hold	196	–	–	0.1%	38
2017 Q1	$175K	Hold	196	–	–	0.11%	35
2016 Q4	$203K	Hold	196	–	–	0.1%	34
2016 Q3	$388K	Sell	196 -31	-14%	-$57.9K	0.18%	34
2016 Q2	$386K	Hold	227	–	–	0.15%	35
2016 Q1	$396K	Buy	+227	New	+$361K	0.15%	36

Other funds holding TRIB

PIM

Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return

SCM

Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return

Proxima Capital Management's TRIB Position: Q4 2017 in Review

Proxima Capital Management sold out of Trinity Biotech (TRIB) in Q4 2017, closing a stake of 196 shares — an estimated $165K sold.

Proxima Capital Management first reported a position in TRIB in Q1 2016 and held it in 7 quarters. The position peaked at $396K in Q1 2016. 47 funds tracked by Wall St. Rank hold TRIB as of Q4 2017.

Proxima Capital Management reported no remaining Trinity Biotech position as of Q4 2017 after selling out during the quarter.
Proxima Capital Management sold 196 Trinity Biotech shares in Q4 2017, an estimated $165K.
Proxima Capital Management first reported a position in Trinity Biotech in Q1 2016 and held it in 7 quarters.
Proxima Capital Management's Trinity Biotech position peaked at $396K in Q1 2016.
47 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2017.

Based on Proxima Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.